This template was built with Webflow's free Prospero UI Kit. Learn more
If your child has received an SCN2A diagnosis and the words “mixed function” have appeared in a genetic report or a conversation with a neurologist, you are not alone in finding the term confusing. Unlike gain of function (GOF) or loss of function (LOF) — which signal a clear directional change in how the Nav1.2 channel behaves — a mixed function classification means something more complicated is happening. Understanding what that means, why it exists as a category, and what it tells us about your child’s biology is the goal of this guide.
Mixed function variants represent the frontier of SCN2A science. They are less well-characterized than GOF and LOF variants, and they are an area of active research. That uncertainty can feel unsettling — but it also reflects how seriously the scientific community is working to understand the full complexity of SCN2A-related disorders. Begin with a foundation by understanding the SCN2A gene, then read on for a plain-language explanation of what mixed function means and why it matters.
The SCN2A gene encodes the Nav1.2 protein — a voltage-gated sodium channel that sits in the membrane of neurons and controls the flow of sodium ions into the cell. This flow of sodium is what generates the electrical signals neurons use to communicate. Nav1.2 is expressed at especially high levels during early brain development, making it a critical player in how the brain forms and organizes its circuits in the first months and years of life. As the brain matures, Nav1.2 is later partially replaced by Nav1.6 at key neuronal regions such as the axon initial segment in excitatory neurons — a developmental transition that helps explain why SCN2A-related phenotypes can differ depending on the age at which they emerge.
Researchers classify SCN2A variants by how they alter Nav1.2 channel function. Gain of function (GOF) variants make the channel overactive — more sodium flows in, neurons become hyperexcitable, and early-onset epilepsy, most commonly emerging within the first months of life, is the most frequent result. Loss of function (LOF) variants do the opposite — the channel is underactive, neurons fire less readily, and the clinical picture is more often associated with autism spectrum disorder (ASD), intellectual disability, and later-onset or absent epilepsy, though presentations vary.
Between these two poles sits a third category: mixed function. Understanding what places a variant in this category — and what it means for the child who carries it — requires looking more closely at how scientists measure channel function.
A sodium channel’s function is not described by a single measurement. Researchers use a range of electrophysiological parameters — measures such as how quickly the channel activates (opens), how quickly it inactivates (closes), how readily it recovers between firings, and how much sodium current it allows through at peak activity. Each of these parameters can shift independently depending on the specific mutation.
A mixed function variant is one where some of these parameters show GOF characteristics — the channel is doing too much in certain respects — while others show LOF characteristics — the channel is doing too little in other respects. In other words, the same mutation can produce both gain- and loss-like effects depending on which functional property or biological context is being measured. In some cases, even a single parameter can have context-dependent effects depending on the voltage range or cell type involved.
Research published in the Journal of General Physiology (Thompson et al., 2023) used high-throughput automated patch-clamp recording to characterize a large cohort of SCN2A variants and found that many epilepsy-associated variants exhibited diverse and sometimes mixed functional effects. The authors noted that these findings suggest the simple binary GOF versus LOF framework “oversimplifies variant effect on channel function and does not fully capture the complete physiological impact of channel dysfunction.” This is not a failure of the science — it is a recognition of the genuine biological complexity that some SCN2A variants produce.
With a pure GOF variant, the net effect on neuronal excitability points in one direction: the neuron fires more easily and more frequently than it should. With a pure LOF variant, the opposite is true: the neuron is less excitable. These directional signals are what give GOF and LOF classifications much of their clinical and therapeutic relevance.
Mixed function variants disrupt this clean picture. Because different electrophysiological parameters are shifted in opposite directions, the net effect on neuronal excitability is harder to predict from the channel measurements alone. One parameter may be pushing the neuron toward hyperexcitability while another is simultaneously pulling it toward hypoexcitability. The overall outcome depends on which effects dominate — and in many cases, that net effect cannot be reliably predicted from channel measurements alone, requiring neuronal modeling or additional in vivo context to interpret. This can vary depending on the developmental stage, the specific brain region, and the cellular environment in which the channel is expressed.
Research analyzing clinical phenotypes and variant function in large SCN2A cohorts has found that GOF variants — and many, though not all, mixed function variants — are frequently associated with neonatal- or early-infantile-onset epilepsy — seizures beginning in the first months of life. This suggests that, despite their biophysical complexity, many mixed function variants produce a net effect that tips the brain toward hyperexcitability in the early developmental period. However, the relationship between mixed function classification and clinical outcome is not uniform, and some mixed function variants are associated with later phenotypes or overlapping features with LOF presentations. Individual children’s presentations can vary considerably.
Because mixed function variants are a heterogeneous group — defined not by a single shared mechanism but by a shared pattern of having mixed mechanisms — the clinical presentations associated with them are correspondingly varied. This is one of the things that makes mixed function the most clinically unpredictable of the three SCN2A variant categories.
In published research, mixed function variants have been most frequently identified in children with neonatal-onset epilepsy, including severe presentations such as developmental and epileptic encephalopathy (DEE). In some cases, partial response to sodium channel blockers has been observed — because some GOF parameters are present — but responses are variable and not reliably predicted by a mixed function classification alone. This variability is one reason why functional characterization of the specific variant is so important, and why all medication decisions should be made with a specialist experienced in SCN2A-related disorders.
Children with mixed function SCN2A variants may also experience developmental impacts beyond seizures, including motor difficulties, communication delays, and other features that vary from child to child. As with all SCN2A-related disorders, a multidisciplinary care team experienced in genetic epilepsies is central to navigating the range of challenges a child may face. You can explore active SCN2A research that is helping build the evidence base for more precisely tailored care approaches across the full spectrum of SCN2A variant types.
It is important for families to know that a mixed function classification does not mean that a child’s variant is unexplained or that nothing is known about it. It means that the biology is genuinely complex — and that the classification reflects both that biological complexity and the current limits of how we measure and interpret channel function. Science is actively working to close that gap.
For families receiving a mixed function classification, one of the most important questions to discuss with a care team is whether the specific variant has been functionally characterized — and if so, by what method. Not all functional characterization approaches are equivalent in what they reveal about how a variant affects neuronal excitability in a living brain.
The traditional method is voltage clamp — a laboratory technique that measures individual electrophysiological parameters of the channel in isolation. Voltage clamp has been the workhorse of ion channel research for decades and provides valuable data. However, research has shown that for many SCN2A variants — particularly those with mixed or complex functional profiles — voltage clamp alone may not fully predict how the variant affects a neuron’s actual firing behavior.
A more recently developed approach, dynamic action potential clamp (DAPC), incorporates the channel’s measured properties into a computational model of a real neuron and asks: how does this variant actually change the way the neuron fires? Research published in Communications Biology (Brunklaus et al., 2022) found that DAPC showed improved ability compared to voltage clamp alone in predicting the clinical phenotypic group (early-infantile versus later-onset epilepsy) associated with specific variants. For mixed function variants, where the net neuronal effect is not obvious from individual parameter measurements, approaches like DAPC may be particularly valuable.
Families can ask their neurologist or geneticist whether their child’s variant has been functionally evaluated, which methods were used, and whether additional characterization through a specialized research center may be appropriate. This conversation is part of the broader precision medicine approach that the SCN2A research community is building toward.
The recognition that many SCN2A variants produce genuinely mixed or complex functional effects is itself a scientific advance. Earlier frameworks treated GOF and LOF as a clean binary — and while that framing remains useful as a first approximation, researchers now understand that the reality is more nuanced. Publications from Northwestern University’s Feinberg School of Medicine (Thompson et al., 2023) and from international research collaborations (Brunklaus et al., 2022; Berg et al., 2024) have all contributed to a more sophisticated picture of how SCN2A variant function maps onto clinical presentation.
This work has direct implications for the precision medicine approaches being developed for SCN2A-related disorders. Targeted therapies are being designed to address specific mechanisms of channel dysfunction — and understanding whether a variant drives hyperexcitability, hypoexcitability, or a combination of both is essential for identifying which approaches may be most relevant to a given child. Families whose children carry mixed function variants have a stake in this research, and the SCN2A patient registry is one of the most direct ways to connect your child’s experience to the science that will shape the next generation of therapies.
For families navigating a mixed function diagnosis today, the most important things to know are these: the classification reflects genuine biological complexity, not a gap in knowledge; functional characterization of the specific variant is worth pursuing through a specialist; and the research community is actively working to better understand this category. The science is evolving, and the SCN2A Foundation is committed to supporting the research that will bring greater clarity to every family — regardless of where on the functional spectrum their child’s variant falls.
Understanding SCN2A mixed function disorders is one of the field’s most active frontiers. Every data point, every characterized variant, and every family who participates in research moves the science forward. The path from biological complexity to clinical clarity runs through the patient community.
Every family navigating an SCN2A mixed function diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider making a donation to help fund the research and resources that move us all forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Share
If your child has received an SCN2A diagnosis and the words “mixed function” have appeared in a genetic report or a conversation with a neurologist, you are not alone in finding the term confusing. Unlike gain of function (GOF) or loss of function (LOF) — which signal a clear directional change in how the Nav1.2 channel behaves — a mixed function classification means something more complicated is happening. Understanding what that means, why it exists as a category, and what it tells us about your child’s biology is the goal of this guide.
Mixed function variants represent the frontier of SCN2A science. They are less well-characterized than GOF and LOF variants, and they are an area of active research. That uncertainty can feel unsettling — but it also reflects how seriously the scientific community is working to understand the full complexity of SCN2A-related disorders. Begin with a foundation by understanding the SCN2A gene, then read on for a plain-language explanation of what mixed function means and why it matters.
The SCN2A gene encodes the Nav1.2 protein — a voltage-gated sodium channel that sits in the membrane of neurons and controls the flow of sodium ions into the cell. This flow of sodium is what generates the electrical signals neurons use to communicate. Nav1.2 is expressed at especially high levels during early brain development, making it a critical player in how the brain forms and organizes its circuits in the first months and years of life. As the brain matures, Nav1.2 is later partially replaced by Nav1.6 at key neuronal regions such as the axon initial segment in excitatory neurons — a developmental transition that helps explain why SCN2A-related phenotypes can differ depending on the age at which they emerge.
Researchers classify SCN2A variants by how they alter Nav1.2 channel function. Gain of function (GOF) variants make the channel overactive — more sodium flows in, neurons become hyperexcitable, and early-onset epilepsy, most commonly emerging within the first months of life, is the most frequent result. Loss of function (LOF) variants do the opposite — the channel is underactive, neurons fire less readily, and the clinical picture is more often associated with autism spectrum disorder (ASD), intellectual disability, and later-onset or absent epilepsy, though presentations vary.
Between these two poles sits a third category: mixed function. Understanding what places a variant in this category — and what it means for the child who carries it — requires looking more closely at how scientists measure channel function.
A sodium channel’s function is not described by a single measurement. Researchers use a range of electrophysiological parameters — measures such as how quickly the channel activates (opens), how quickly it inactivates (closes), how readily it recovers between firings, and how much sodium current it allows through at peak activity. Each of these parameters can shift independently depending on the specific mutation.
A mixed function variant is one where some of these parameters show GOF characteristics — the channel is doing too much in certain respects — while others show LOF characteristics — the channel is doing too little in other respects. In other words, the same mutation can produce both gain- and loss-like effects depending on which functional property or biological context is being measured. In some cases, even a single parameter can have context-dependent effects depending on the voltage range or cell type involved.
Research published in the Journal of General Physiology (Thompson et al., 2023) used high-throughput automated patch-clamp recording to characterize a large cohort of SCN2A variants and found that many epilepsy-associated variants exhibited diverse and sometimes mixed functional effects. The authors noted that these findings suggest the simple binary GOF versus LOF framework “oversimplifies variant effect on channel function and does not fully capture the complete physiological impact of channel dysfunction.” This is not a failure of the science — it is a recognition of the genuine biological complexity that some SCN2A variants produce.
With a pure GOF variant, the net effect on neuronal excitability points in one direction: the neuron fires more easily and more frequently than it should. With a pure LOF variant, the opposite is true: the neuron is less excitable. These directional signals are what give GOF and LOF classifications much of their clinical and therapeutic relevance.
Mixed function variants disrupt this clean picture. Because different electrophysiological parameters are shifted in opposite directions, the net effect on neuronal excitability is harder to predict from the channel measurements alone. One parameter may be pushing the neuron toward hyperexcitability while another is simultaneously pulling it toward hypoexcitability. The overall outcome depends on which effects dominate — and in many cases, that net effect cannot be reliably predicted from channel measurements alone, requiring neuronal modeling or additional in vivo context to interpret. This can vary depending on the developmental stage, the specific brain region, and the cellular environment in which the channel is expressed.
Research analyzing clinical phenotypes and variant function in large SCN2A cohorts has found that GOF variants — and many, though not all, mixed function variants — are frequently associated with neonatal- or early-infantile-onset epilepsy — seizures beginning in the first months of life. This suggests that, despite their biophysical complexity, many mixed function variants produce a net effect that tips the brain toward hyperexcitability in the early developmental period. However, the relationship between mixed function classification and clinical outcome is not uniform, and some mixed function variants are associated with later phenotypes or overlapping features with LOF presentations. Individual children’s presentations can vary considerably.
Because mixed function variants are a heterogeneous group — defined not by a single shared mechanism but by a shared pattern of having mixed mechanisms — the clinical presentations associated with them are correspondingly varied. This is one of the things that makes mixed function the most clinically unpredictable of the three SCN2A variant categories.
In published research, mixed function variants have been most frequently identified in children with neonatal-onset epilepsy, including severe presentations such as developmental and epileptic encephalopathy (DEE). In some cases, partial response to sodium channel blockers has been observed — because some GOF parameters are present — but responses are variable and not reliably predicted by a mixed function classification alone. This variability is one reason why functional characterization of the specific variant is so important, and why all medication decisions should be made with a specialist experienced in SCN2A-related disorders.
Children with mixed function SCN2A variants may also experience developmental impacts beyond seizures, including motor difficulties, communication delays, and other features that vary from child to child. As with all SCN2A-related disorders, a multidisciplinary care team experienced in genetic epilepsies is central to navigating the range of challenges a child may face. You can explore active SCN2A research that is helping build the evidence base for more precisely tailored care approaches across the full spectrum of SCN2A variant types.
It is important for families to know that a mixed function classification does not mean that a child’s variant is unexplained or that nothing is known about it. It means that the biology is genuinely complex — and that the classification reflects both that biological complexity and the current limits of how we measure and interpret channel function. Science is actively working to close that gap.
For families receiving a mixed function classification, one of the most important questions to discuss with a care team is whether the specific variant has been functionally characterized — and if so, by what method. Not all functional characterization approaches are equivalent in what they reveal about how a variant affects neuronal excitability in a living brain.
The traditional method is voltage clamp — a laboratory technique that measures individual electrophysiological parameters of the channel in isolation. Voltage clamp has been the workhorse of ion channel research for decades and provides valuable data. However, research has shown that for many SCN2A variants — particularly those with mixed or complex functional profiles — voltage clamp alone may not fully predict how the variant affects a neuron’s actual firing behavior.
A more recently developed approach, dynamic action potential clamp (DAPC), incorporates the channel’s measured properties into a computational model of a real neuron and asks: how does this variant actually change the way the neuron fires? Research published in Communications Biology (Brunklaus et al., 2022) found that DAPC showed improved ability compared to voltage clamp alone in predicting the clinical phenotypic group (early-infantile versus later-onset epilepsy) associated with specific variants. For mixed function variants, where the net neuronal effect is not obvious from individual parameter measurements, approaches like DAPC may be particularly valuable.
Families can ask their neurologist or geneticist whether their child’s variant has been functionally evaluated, which methods were used, and whether additional characterization through a specialized research center may be appropriate. This conversation is part of the broader precision medicine approach that the SCN2A research community is building toward.
The recognition that many SCN2A variants produce genuinely mixed or complex functional effects is itself a scientific advance. Earlier frameworks treated GOF and LOF as a clean binary — and while that framing remains useful as a first approximation, researchers now understand that the reality is more nuanced. Publications from Northwestern University’s Feinberg School of Medicine (Thompson et al., 2023) and from international research collaborations (Brunklaus et al., 2022; Berg et al., 2024) have all contributed to a more sophisticated picture of how SCN2A variant function maps onto clinical presentation.
This work has direct implications for the precision medicine approaches being developed for SCN2A-related disorders. Targeted therapies are being designed to address specific mechanisms of channel dysfunction — and understanding whether a variant drives hyperexcitability, hypoexcitability, or a combination of both is essential for identifying which approaches may be most relevant to a given child. Families whose children carry mixed function variants have a stake in this research, and the SCN2A patient registry is one of the most direct ways to connect your child’s experience to the science that will shape the next generation of therapies.
For families navigating a mixed function diagnosis today, the most important things to know are these: the classification reflects genuine biological complexity, not a gap in knowledge; functional characterization of the specific variant is worth pursuing through a specialist; and the research community is actively working to better understand this category. The science is evolving, and the SCN2A Foundation is committed to supporting the research that will bring greater clarity to every family — regardless of where on the functional spectrum their child’s variant falls.
Understanding SCN2A mixed function disorders is one of the field’s most active frontiers. Every data point, every characterized variant, and every family who participates in research moves the science forward. The path from biological complexity to clinical clarity runs through the patient community.
Every family navigating an SCN2A mixed function diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider making a donation to help fund the research and resources that move us all forward.
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Vlad Magdalin
